Skip to main content

Table 4 Coagulation parameters mean values for healthy Beagle dogs treated with enflicoxib orally once a week for up to 7 months (SD)

From: Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months

Treatment group   0X 1X 3X 5X  
Dose (loading+maintenance)   (Placebo) (8 + 4 mg/kg) (24 + 12 mg/kg) (40 + 20 mg/kg) Pa
Prothrombin time (sec) (PT) Basal 8,01 (0,35) 7,85 (0,53) 7,65 (0,39) 7,73 (0,34) ns
  Week 4 8,13 (0,48) 7,89 (0,58) 7,65 (0,57) 7,68 (0,45) ns
  Week 8 8,28 (0,35) 8,38 (0,57) 7,96 (0,52) 7,84 (0,40) ns
  Week 13 8,15 (0,39) 8,05 (0,43) 7,68 (0,39) 7,78 (0,36) ns
  Week 17 8,03 (0,44) 7,99 (0,60) 7,84 (0,68)   ns
  Week 21 8,26 (0,40) 8,16 (0,46) 7,99 (0,65)   ns
  Week 25 8,38 (0,42) 8,24 (0,41) 7,78 (0,49)   ns
  Week 30 8,04 (0,23) 7,98 (0,41) 7,61 (0,38)   ns
Activated partial thromboplastin time (sec) (APTT) Basal 16,1 (1,0) 15,7 (1,4) 16,2 (0,9) 16,0 (0,9) ns
  Week 4 15,6 (0,9) 15,5 (0,7) 15,6 (0,5) 15,3 (0,8) ns
  Week 8 16,0 (0,8) 15,6 (0,6) 15,7 (0,6) 15,5 (1,0) ns
  Week 13 15,8 (0,6) 15,3 (0,7) 15,1 (0,2) 14,9 (0,8) ns
  Week 17 15,3 (1,0) 15,1 (0,9) 15,3 (1,0)   ns
  Week 21 15,4 (0,6) 14,9 (0,8) 15,2 (0,4)   ns
  Week 25 15,6 (0,7) 15,1 (0,7) 15,2 (0,3)   ns
  Week 30 15,0 (0,6) 14,6 (0,4) 14,7 (0,3)   ns
Fibrinogen concentration (g/L) (Fib) Basal 2,43 (0,76) 2,10 (0,46) 2,26 (0,61) 1,96 (0,27) ns
  Week 4 2,22 (0,54) 1,95 (0,52) 2,06 (0,43) 1,77 (0,44) ns
  Week 8 2,09 (0,59) 1,91 (0,51) 1,85 (0,24) 2,56 (0,75) ns
  Week 13 1,97 (0,41) 1,93 (0,19) 2,02 (0,22) 1,72 (0,25) ns
  Week 17 2,01 (0,39) 1,90 (0,26) 1,91 (0,26)   ns
  Week 21 2,40 (0,47) 2,19 (0,27) 2,09 (0,31)   ns
  Week 25 2,20 (0,36) 2,03 (0,19) 1,89 (0,35)   ns
  Week 30 1,90 (0,48) 1,93 (0,20) 2,15 (0,63)   ns
  1. aTreated groups compared with 0X group using Williams’ test (ns: p > 0.05, * p < 0.05, ** p < 0.01)
  2. N = 4 animals/sex/treatment group